Research on lung cancer detection and treatment. Covers microbial predictors of immunotherapy, MRI detection, microplastics, and RAS-mutant drugs.
Researchers discovered 171 distinct mutations causing MET exon 14 skipping in lung cancer patients. RNA-based testing confirmed these alterations, highlighting the importance of complementary diagnostic approaches.
A new study by McGill researchers provides detailed insights into how quitting smoking affects the human lung at the cellular level. Quitting appears to leave lasting changes in genes linked to tissue structure, immune function, and blood vessel health in some lung cells.
A cohort study of Korean patients with lung cancer found that international screening guidelines excluded 64.6% of patients, many without smoking history. Ineligible patients had lower mortality risk than eligible patients, suggesting tailored approaches are necessary to enhance early detection.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found significant sex-based protein differences in lung adenocarcinoma, with 901 proteins varying between male and female patient samples. This study contributes to understanding cancer biology and may benefit physicians and patients.
A new study has identified two naturally occurring microRNAs, microRNA-15a and microRNA-16, which can significantly reduce the growth and protein synthesis of non-small cell lung cancer cells. This finding suggests that these microRNAs could serve as targets for therapies designed to slow cancer progression.
The Association for Molecular Pathology recognizes Dartmouth Health medical director Laura J. Tafe for her exceptional leadership and dedication to the field of molecular diagnostics. She has been a member of the organization since 2007 and has held various positions, including president in 2023.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
Researchers have developed an innovative combination treatment strategy that uses cells' waste removal functions to effectively dismantle multiple myeloma. The experimental targeted protein degrader enhances the destruction of a specific cancer cell survival protein and works in tandem with existing drugs, while showing limited toxicity.
Scientists have developed a non-invasive method to predict gene changes causing lung cancer using fluorescence lifetime imaging microscopy (FLIM). This approach can identify specific genetic mutations, such as EGFR, with high accuracy and speed, preserving limited biopsy material for further analysis.
A study published in Cancer Cell identified a six-gene signature in microscopic colorectal cancer liver metastases that may help predict recurrence after treatment. The findings suggest these tiny tumor deposits could serve as a tissue-based marker of residual cancer cells, recurrence risk and chemotherapy resistance.
A new study reveals that lung tumors can cause cachexia by hacking into the nervous system and altering eating behavior. Researchers found that tumors missing a gene called LKB1 produced prostaglandin E2, a signaling molecule that amplifies inflammation and causes weight loss.
The respiratory microbiota drives lung cancer through four integrated pathways: oncogenic signaling, epigenetic/metabolic reprogramming, chronic immune dysregulation. Microbial signatures can predict diagnosis, staging, and therapy response.
A new study by Thales Papagiannakopoulos and colleagues found that lung cancer tumors talk directly to the nervous system through sensory neurons in the lungs, promoting cachexia. Silencing these nerves or blocking the production of prostaglandin E2 (PGE2) reduced cachexia, suggesting a potential therapeutic strategy.
A genomic study found two previously unreported truncating germline variants in BRCA2, suggesting inherited alterations may contribute to susceptibility to multiple primary lung cancers. The study also points toward important clinical applications, including the use of PARP inhibitors and molecularly targeted approaches for treatment.
Emerging evidence positions lactylation as a critical metabolic-epigenetic hub in lung cancer. Lactylation drives oncogenic programs and immune-evasion pathways, contributing to treatment resistance. Targeting this axis may restore treatment sensitivity.
A University of Arizona research team has developed a nanotechnology-based platform combining paclitaxel with siRNA to enhance the immune response against lung cancer. The approach exploits an 'eat me' signal on dying cancer cells, attracting immune cells and initiating tumor death.
A new study found that socioeconomic challenges hinder lung cancer screening adherence and equity, highlighting the need for targeted interventions to improve patient experience. Lower-income participants reported greater discomfort or anxiety during low-dose chest CT screening.
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
Researchers found that patients often wait an average of four weeks for biomarker test results, with the first step taking up to 23 days to order testing. This delay can lead to mismatched therapies, toxic side effects, and reduced treatment options, emphasizing the need for improved testing turnaround times.
Researchers identify CLASS 3G subtype of EGFR mutation associated with limited response to targeted drugs. This structural subtype alters protein shape, reducing treatment efficacy and allowing for more effective combination therapy.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
A new national analysis found that mesothelioma deaths and diagnoses continue to rise in the US, with little improvement in survival rates. The disease disproportionately affects women and several high-risk states tied to shipbuilding, mining, and legacy asbestos exposure.
A 14-protein signature in the blood can predict lung cancer risk more than five years before diagnosis, according to researchers at the Francis Crick Institute. The team used machine learning on plasma data from over 48,000 people to identify the signature, which reflects an altered inflammatory lung environment.
Researchers analyzed tumor samples from over a thousand patients and found that TP53 gene mutations can worsen prognosis and reduce effectiveness of targeted therapies. The study suggests incorporating genetic testing into public health services to guide personalized treatment choices.
The study found that adjuvant nivolumab did not improve disease-free survival in patients with resected non–small cell lung cancer. The treatment was also not effective in sensitizing EGFR and ALK alterations.
A new study shows that targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare genetic subtype. After two years, 92% of patients remained cancer-free, compared to 61% who received a placebo.
A population-based screening trial evaluating a cell-free DNA multicancer early detection test found modest increases in diagnostic delay rates for head and neck, lung, and upper gastrointestinal cancers. These findings suggest that future trials may need to consider system-level spillover effects on healthcare resources.
The WU-KONG28 trial found that sunvozertinib significantly extended progression-free survival to over 10 months, compared to 7.5 months with chemotherapy alone. The treatment also shrank tumors in 58.9% of patients.
A new study published in JAMA found that using a cryoprobe for lung biopsies significantly increases the diagnostic yield compared to standard forceps, with nearly 10 percentage points higher accuracy. The 1.1-millimeter cryoprobe was shown to be safer and more effective than larger probes without crushing tissue samples.
Severe obstructive sleep apnea is associated with higher lung cancer incidence and mortality, driven by mechanisms such as HIF activation, immune remodeling, and enhanced cancer stem cell properties. Long-term adherent CPAP therapy shows promise in mitigating these risks.
Researchers from Ohio State University Comprehensive Cancer Center present new findings on a hospital program that redistributes unused oral cancer drugs donated by patients. The program helps patients avoid treatment delays caused by insurance issues, shipping problems or cost, and has been shown to reduce drug delays by six days.
Researchers discovered that degrading mutant KRAS protein leads to greater lung cancer regression and more durable antitumor responses than conventional inhibitors. The study also identifies resistance mechanisms distinct from those previously described, offering new insights into targeted protein degradation therapies.
Researchers discovered lung cancer cells change identity to resist treatment by reactivating a process involved in early lung development. This could help doctors predict which patients respond well to treatment and provide personalized care.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
Researchers from ECOG-ACRIN Cancer Research Group will present updated outcomes from the STAMP study on Merkel cell carcinoma, primary results from studies in glioblastoma and non-small cell lung cancer, and emerging approaches in precision oncology. AI-driven insights from the TAILORx breast cancer trial will also be showcased.
The LUNA-2 trial will pair immunotherapy with fecal microbiota transplantation (FMT) to boost treatment effectiveness in people with non-small cell lung cancer. If successful, it could provide new treatment options for those living with the disease, helping them live longer and with fewer side effects.
A USC-led study analyzed insurance claims data from 940 patients with ALK-positive non-small cell lung cancer to compare the effectiveness of five tyrosine kinase inhibitors. The results showed alectinib and lorlatinib as promising treatments, offering longer survival times and better treatment duration compared to other options.
The Alliance A082402 study evaluates the effectiveness of involved-station I²-PORT in reducing NSCLC recurrence without long-term side effects. Participants will undergo randomized treatment with or without targeted radiation therapy after surgery.
Researchers at UT MD Anderson Cancer Center have made significant advancements in cancer care, including the development of a targeted RAS inhibitor therapy for pancreatic cancer and a biomarker of chemotherapy resistance in relapsed lung cancer. The studies also explore the tumor microenvironment of triple-negative breast cancer and i...
A new study found that diaphragmatic dome height on chest X-rays is a practical prognostic marker for predicting long-term outcomes and respiratory-related deaths in lung cancer patients with breathing disorders. Lower DDH before surgery was associated with poorer survival rates.
Researchers developed a novel diagnostic support framework using visual question answering to generate interpretable findings from chest CT images. The system demonstrated strong agreement with reference descriptions and provided clinically meaningful outputs.
A study published in JAMA Oncology reveals that nearly half of patients with metastatic non-small-cell lung cancer never receive treatment, highlighting a significant gap in care. The research emphasizes the importance of referring patients promptly to an oncologist and improving access to life-saving treatments.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
Researchers have discovered a biomarker for chemotherapy resistance in small cell lung cancer, which can help identify cells that become more invasive and lead to treatment resistance. Targeting these cells with YAP1 may be a possible strategy to improve patient outcomes.
Researchers at UT MD Anderson Cancer Center have made significant advancements in targeted therapy treatments for advanced lung cancer and early-stage classical Hodgkin lymphoma. The studies showcase high response rates with novel combination therapies and a new understanding of how an enzyme affects infertility and cancer progression.
Researchers introduce Radon transform-based flow measurement (R-Flow), a contrast-free ultrasound method that visualizes blood flow dynamics at the microvascular scale. The technique captures complete 2D flow patterns and demonstrates high accuracy in detecting pathological changes in diseases like cirrhosis.
A first-in-human clinical trial found that setidegrasib, a targeted therapy drug, demonstrated early antitumor activity in advanced lung and pancreatic cancers. The therapy shrank tumors and delayed disease progression in some patients, providing a potential new treatment approach for KRAS G12D-driven cancers.
EGFR-TKIs have significantly improved OS and quality of life for EGFR-mutant NSCLC patients. However, ongoing research is needed to refine therapies for precise individualized treatment, addressing resistance mechanisms and optimal combination strategies.
A study published in PLOS Medicine found that age at initial diagnosis, sex, and type of first cancer significantly affect the risk of developing a subsequent primary cancer. Older age and male sex were associated with a higher risk, while survivors of lung, bladder, and skin melanoma were also at increased risk.
A new study from Tulane University found that extra sets of chromosomes in tumor cells make them more mobile and likely to engulf neighboring cells. This stress response triggers an abundance of proteins, reprogramming the cells for motility and phagocytosis.
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
The study found a concerning trend towards trial consolidation at top-performing sites in the US, with more limited access to clinical trials for lower-volume locations. This may be due to factors such as increased complexity of phase I trials and regulatory burdens.
Researchers developed a pathomics framework using a deep learning survival prediction model that analyzes pathology slide images and study patterns to predict patient outcomes. The model correctly stratified patients into high- and low-risk groups with significantly different outcomes.
Researchers found a promising response rate of 52% and disease control rate of 93% in patients treated with zoldonrasib. The study also showed favorable safety and tolerability profiles, with no grade 4 treatment-related adverse events observed.
A new study found that elisrasib, a next-generation KRAS-G12C inhibitor, demonstrated a favorable safety and tolerability profile. In patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), elisrasib showed promising response rates of 58.8% and disease control rate of 98.5%. The treatment also improved outcomes...
A rare scalp reaction resembling erosive pustular dermatosis was identified in a lung cancer patient treated with amivantamab following cranial radiotherapy. The reaction appeared to be related to impaired wound healing due to dual inhibition of EGFR and MET signaling pathways.
Researchers from UT MD Anderson Cancer Center present studies on single-cell technologies, integrative computational approaches, and experimental therapeutics, highlighting innovations in mRNA vaccines and spatial multi-omics techniques. The studies aim to improve immunotherapy responses and detect treatment-resistant glioma cells.
The study projects that cancer rates in Canada will be high in 2026, with declines seen in some cancers like colorectal and leukemia. However, death rates from pancreatic cancer are increasing.
A new study maps how rare mixed tumors evolve into hybrid cell states and immune-protected neighborhoods, pointing to new ways to detect and treat combined small-cell lung cancer. The findings reveal that these tumors do not arise from two separate cancers but rather from a single ancestral cell that evolves over time.
Researchers found no association between occupational talc exposure and increased risk of lung cancer, mesothelioma, or laryngeal cancer when talc is free from asbestos contamination. The study suggests continued monitoring of occupational groups to better understand any potential low-level risks.